Investigational drug · Phase 2
LBL-033
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "LBL-033"
First trial start
2023
Apr 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LBL-033", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LBL-033" as an intervention, largest first.
Nanjing Leads Biolabs Co.,LtdIndustry
NCT05779163 · 26 participants · Start Apr 14, 2023 · Primary completion Apr 3, 2025
Drug: LBL-033 for Injection · For: Advanced Malignant Tumors
Sites: Fuzhou, China; Guangzhou, China; Zhengzhou, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Malignant Tumors
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- IAP0971Phase 23 trials
SUNHO(China)BioPharmaceutical CO., Ltd. · Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer
- IBB0979Phase 22 trials
SUNHO(China)BioPharmaceutical CO., Ltd. · Small Cell Lung Cancer, Advanced Malignant Tumors
- JMT108Phase 22 trials
Shanghai JMT-Bio Inc. · Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.